In this article, I noted the prospects that this company is achieving regarding the development of its pipeline drug known as pegozafermin for the treatment of patients with metabolic-associated ...
Additionally, the ongoing Phase 3 ENLIGHTEN program in NASH, which investigates pegozafermin in both non-cirrhotic and cirrhotic conditions, has garnered significant interest from key opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback